A new pharma launch paradigm: From one size fits all to a tailored product approachMichael KunstLoic Plantevin
Opicapon Capsules, was officially accepted by CDE, and now the import application has also been accepted. With the introduction of this Opicapon capsule by Fosun Pharma and its application for market launch in China, it means that it is expected to benefit...
With the increasing demand for the dietary supplement industry in our lives, many nutraceutical brands are emerging to make optimal nutrition accessible to all. Founded in 2018, Himalayan Organics is an Indore-based venture that aims to provide holistic wellness solutions to address various daily heal...
chewable, orally-disintegrating, and film strip dosage forms that can accommodate the unique needs of a wide variety of patients. Tris’ fully integrated research, manufacturing, medical and commercial facilities are located in Central New Jersey. For more information, please visitwww.trispharma.com ...
New Product DevelopmentProject Management 254 Qualitative Study on New Product Development in Pakistan's Pharma Industry 6 Pages 2870 Words New product development is an important success process, which is required for continuous development and long-term growth of the company in pharmaceuticals. ...
The ONLY conference dedicated to the new product planning role and related functions to make informed, value-based, data-driven decisions, from the team behind Fierce Pharma and Fierce Biotech!
In support of Aptar’s commitment towards customer centricity, Aptar India launched five new products during the second edition of “Mega Launch”, Aptar India’s product launch platform that began in May 2019. This edition was centered around customer feedback, “You said it, we made i...
In 2020 alone, WuXi Chemistry's successfully delivered over 1200 drug product batches to partners around the world. In addition, WuXi Chemistry successfully supported the launch of InnoCare's Orelabrutinib in China market, providing end-to-end support including drug substance, amorphous solid ...
In addition, Big Pharma is moving away from the current “blockbuster” focus to a more diversified focus, which may include trying to reduce the risk of systemic therapies and increasing the chances of getting a new molecule through the development and approval process Correspondence: William H....
Hundreds of Fortune 500 new-product teams have used AIM Institute training and software to…Understand what customers want in a new product (New Product Blueprinting) Launch their new product explosively (LaunchStar® methodology) Avoid “landmines” that blow up high-stakes projects (Minesweeper...